Breast Cancer Core Needle Biopsy (CNB) Market Size & Share 2024 to 2032

Breast Cancer Core Needle Biopsy Market Size

Breast Cancer Core Needle Biopsy Market size was valued at USD 776.5 million in 2023 and is estimated to grow at a CAGR of 7.8% from 2024 to 2032. The market has experienced substantial growth due to the rising incidence of breast cancer, which has significantly increased the demand for early diagnosis.

For instance, according to the World Health Organization (WHO), approximately 2.3 million women were diagnosed with breast cancer globally in 2022. This trend has led to a higher adoption of various biopsy techniques, including CNB, thereby fuelling market growth. Additionally, growing awareness among women about the importance of early breast cancer diagnosis has surged the demand for cancer screening programs. As more women participate in these programs, there is an increased need for minimally invasive diagnostic procedures like CNB.
 

This rising demand for cancer screening and diagnostic facilities has been a significant driver of market growth for breast cancer core needle biopsy. Furthermore, advancements in imaging technology and breast biopsy devices are improving the accuracy and safety of CNB, further driving its adoption in both developed and emerging markets.
 

CNB refers to a minimally invasive diagnostic procedure used to extract a small core of tissue from a suspicious area in the breast for pathological examination. This procedure is critical for diagnosing breast cancer, providing detailed tissue architecture that helps determine the presence and type of cancer cells. CNB is typically guided by imaging technologies.
 

Breast Cancer Core Needle Biopsy Market Trends

Growing awareness and screening programs are expected to drive market demand for breast cancer core needle biopsy (CNB) by increasing the number of women undergoing regular breast cancer screenings. Public health campaigns and educational initiatives have highlighted the importance of early detection, leading to more women seeking diagnostic procedures.
 

• For instance, in December 2022, Fujifilm India Pvt Ltd hosted an event in Bhubaneshwar, Odisha, to emphasize the importance of early breast cancer detection through advanced digital mammography. The event featured the AMULET Innovality with CEDM technology at NIDAN Diagnostic, aiming to enhance diagnostic accuracy. This innovative tool supports earlier detection, potentially reducing late-stage diagnoses and treatment complexities.
   
• This promotional focus on early diagnosis and screening programs is expected to increase the number of diagnostic procedures, thereby boosting demand for CNB and fostering overall market growth.
   
• Additionally, the need for ongoing monitoring and assessment of cancer patients further expands the market, as repeat biopsies become essential for effective treatment management.
   

Breast Cancer Core Needle Biopsy Market Analysis

Based on image-guidance technology, the market is segmented into stereotactic-guided, ultrasound-guided, and magnetic resonance imaging (MRI)-guided. The ultrasound-guided segment dominated the market and is anticipated to grow at 7.6% CAGR over the forecast period.
 

• Ultrasound-guided CNB's dominance was asserted due to its high accuracy and non-invasive nature. This technique uses real-time ultrasound imaging to precisely locate and target suspicious breast tissue, ensuring that the biopsy samples are obtained from the exact area of concern.
   
• Additionally, its advantages include reduced procedure time, minimal discomfort for patients, and immediate visualization of the biopsy site, all of which contribute to its widespread adoption.
   
• Moreover, its cost-effectiveness and ease of integration into clinical practice have further bolstered its dominance in the breast cancer core needle biopsy (CNB) market.

Learn more about the key segments shaping this market

Download Free PDF

Based on the end-user, the breast cancer core needle biopsy market is categorized into hospitals, cancer research centers, diagnostic centers, and research & academics. The hospitals segment accounted for the highest market share of 48.4% in 2023.
 

• The hospital's dominance was attributed to its comprehensive diagnostic capabilities and advanced facilities. Hospitals offer a range of imaging technologies, such as ultrasound and mammography, integrated with biopsy procedures, ensuring high accuracy and patient care standards.
   
• These facilities also benefit from their capacity to handle complex cases, provide specialized medical teams, and offer follow-up care, enhancing the overall diagnostic process.
   
• Furthermore, their large patient volumes and established infrastructure contribute to the dominance of hospitals in the core needle biopsy (CNB) market, driving widespread adoption and consistent use of these diagnostic procedures.

U.S. breast cancer CNB market size accounted for USD 320.3 million in 2023.
 

• The U.S. holds a prominent position largely due to several key factors, such as the high incidence of breast cancer and the increased demand for effective diagnostic procedures.
   
• For instance, according to the American Cancer Society, about 1 in 8 women, or approximately 13% of the female population in the U.S., will develop breast cancer in their lifetime. In 2024, it is estimated that breast cancer will account for around 30% of all new female cancer diagnoses. This underscores the critical need for effective diagnostic tools and procedures to manage and treat the disease promptly, thereby augmenting market demand.
   
• Additionally, continuous technological advancements in biopsy devices and favorable reimbursement policies further support market growth.
   

Germany holds a prominent position in the European breast cancer core needle biopsy market.
 

• Germany's prominence in the European breast cancer core needle biopsy (CNB) market is attributed to its advanced healthcare infrastructure and leading-edge diagnostic technologies. The country’s robust medical research environment and high standards of patient care drive the adoption of innovative CNB techniques.
   
• In addition, a strong focus on early detection and precision in breast cancer diagnosis, supported by advanced imaging systems and skilled medical professionals, contributes to its leadership in the market.
   
• Moreover, strong government support for healthcare advancements and widespread access to advanced diagnostic tools further solidify Germany's position as a key player in the European market.
   

Asia Pacific breast cancer core needle biopsy market is poised for rapid growth with a CAGR of 8.2% during the forecast period.
 

• Asia Pacific is poised for rapid growth due to the increasing incidence of breast cancer, expanding healthcare infrastructure, and rising awareness about early detection.
   
• Improved access to advanced diagnostic technologies and growing investments in medical facilities are enhancing the availability of CNB procedures.
   
• Moreover, government initiatives and public health campaigns are promoting regular screenings. As a result, the region's diverse and large population, coupled with advancements in imaging techniques, is driving significant market expansion and the adoption of CNB as a preferred method for accurate breast cancer diagnosis.
   

Breast Cancer Core Needle Biopsy Market Share

The breast cancer core needle biopsy (CNB) market is characterized by innovation and advanced imaging solutions. Key competitors focus on enhancing precision, minimizing patient discomfort, and improving biopsy outcomes through cutting-edge technology. Companies invest in developing minimally invasive devices with real-time imaging capabilities, such as ultrasound and MRI-guided systems.
 

Breast Cancer Core Needle Biopsy Market Companies

Few of the prominent players operating in the breast cancer core needle biopsy (CNB) treatment industry include:

• Aurora Imaging Technology Inc. 
• BD
• Devicor Medical Products, Inc.
• Fujifilm Holdings
• Hologic, Inc. 
• Insight Medbotics
• McLaren 
• Rye Radiology
• Siemens Healthcare Private Limited
• Sentinelle Medical Inc.
• Tampa General
   

Breast Cancer Core Needle Biopsy Industry News:

• In May 2024, Hologic, Inc. introduced the 7-gauge needle for the Brevera Breast Biopsy System in Europe. This new addition to the Brevera Disposable Biopsy Needles enhanced the range of options available to radiologists for breast biopsy procedures. The launch expects to provide enhanced options for more accurate and efficient breast cancer core needle biopsy procedures.
   
• In September 2023, The FDA granted 510(k) clearance for the IGAR system, a robotic guidance and placement system compatible with MRI. Developed by Insight Medbotics, it is the first robotics system approved for use inside an MRI bore, specifically for breast biopsy procedures. This advancement enhances precision in MRI-guided breast biopsies, potentially improving diagnostic outcomes.
   

The breast cancer core needle biopsy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Image-guidance Technology

• Stereotactic-guided
• Ultrasound-guided
• Magnetic resonance imaging (MRI)-guided 

Market, By End-user

• Hospitals
• Cancer research centers
• Diagnostic centers
• Research and academics

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa